Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Idrofos
Generic Name Ibandronic acid
Other Brand Name Bonviva, Idrofos
Packing 1
Manufacturer Sun pharma
Form Syringe
Strength 3mg X 3ml

  • 3mg X 3ml Syringe $68.00
Available online
More Views

Similar Product

  • Generic Boniva, Ibandronic Acid

    Generic Name:Ibandronic Acid
    Form:Tablet
  • Bondronat Ampule

    Generic Name:Ibandronic acid
    Form:Ampule
    Out of Stock
  • Bonviva

    Generic Name:Ibandronic acid
    Form:Tablet
    Out of Stock
  • Generic Boniva, Ibandronic acid Injection

    Generic Name:Ibandronic acid
    Form:Injection
  • Idrofos KIT, Ibandronic Acid/ Calcium/ Vitamin D3

    Generic Name: Ibandronic Acid/ Calcium/ Vitamin D3
    Form: Tablets
  • Calinta Kit, Calcium/ Calcitriol/ Zinc/ Ibandronic Acid

    Generic Name:Calcium/ Calcitriol/ Zinc/ Ibandronic Acid
    Form:Tablet
  • Osteokit, Calcium/ Calcitriol/ Zinc/ Ibandronic Acid

    Generic Name:Calcium/ Calcitriol/ Zinc/ Ibandronic Acid
    Form:Capsule and Tablet
  • Rockbon Kit, Ibandronic Acid/ Calcium/ Vitamin D3

    Generic Name:Ibandronic Acid/ Calcium/ Vitamin D3
    Form:Tablet
  • Flurish, Ibandronic Acid

    Generic Name:Ibandronic Acid
    Form:Tablet
< >

1 1 1 1 1 1 1 1 1

Details

Introduction

Ibandronic acid is a bisphosphonate containing nitrogen and is responsible for inhibiting osteoclast mediated bone resorption. This drug is also available as Ibandronic Sodium and is whitish in color and is freely soluble in water and therefore can be given as injection. Boniviva injection contains Ibandronic Sodium monophosphate equivalent to about 3 mg of Ibandronic acid. This is a drug that binds to hydroxyapatite in bone and increases the bone density. Its use is in post menopausal women with lack of estrogen which is responsible for their low bone density and osteoporosis formation.


Use

This drug is primarily an agent for the formation of bone tissue by increasing the concentration of osteocytes as it helps in preventing the eating away of the bony hydroxyapatite portion by increased osteoclastic activity. Ibandronic acid is used for the postmenopausal osteoporosis in women, because they are lacking estrogen. Since, it is administered once in every 3 months, it can be effective and has patient compliance. It is known to increase the bone mass density in the osteoporotic women.


Side effects

Renal impairment can be seen due to the lowering of creatinine levels. Osteonecrosis of the jaw is one of the leading side effects, especially in people who have already diseases of the jaw or some dental invasive procedure has been done. Muscle pain has been observed in patients during the post marketing surveillance. This usually happens in the subtrochanteric and femoral areas. Even fractures have been known to be caused due to the injection of Ibandronic acid. Tests have not be conclusive about the mutagenic, carcinogenic and infertility effects. Even, safety in paediatric patients has not been established.


Contraindication

Having any known allergy or contraindications to the drug is one of the primary contraindications. People with hypocalcemia which is uncorrected can be not given the drug. Like any other Bisphosphonates, they can cause decrease in calcium levels. It should not be used by any other route except intravenously due to the fear of necrosis. Patients with sufficient levels of calcium or intake of adequate amounts should be administered the injection. Decreased creatinine level should be checked or else there can be renal impairment. Those who are simultaneously receiving bisphosphonates shouldn't be given the drug as it may add to the total calcium requirement.


storage

Injection of Ibandronic acid is stored at 25Ã


Composition

The injection consists of Ibandronic acid in liquid form which is available as prefilled syringes. They come in amounts of 3 mg of the drug in 3 ml volume in syringes which are of a total volume of 5 ml. These injections are to be administered for the purpose of treatment of postmenopausal osteoporosis at values of 3 mg once in every 3 months. Since they can only be administered intravenously, they should be carefully injected over a period of around 15 to 20 seconds.


Important Precautions

Allergy to this drug or any other drug is to be asked from the patient. Specific history of any calcium metabolism disorder or hypocalcaemia is to be checked. Along with this drug, other bisphosphonates cannot be administered. Pregnancy and kidney diseases are asked before prescribing these drugs.


Dosage and administration

The injection comes in doses of 3 mg in 3ml prefilled syringes and is given to the patients once in every 3 months. They have to be given by intravenous route only and not by subcutaneous or intraarterial route as it might cause tissue damage. It should not be used before 3 months are over.